When an M&A transaction involves a third party with an outstanding and attractive proposition

Metsera, Inc. is a biopharmaceutical company with strategically positioned R&D assets, particularly in the area of chronic weight management, a highly competitive target market. Initially, Metsera had an existing merger agreement with Pfizer Inc.

Source: RTT News

On October 29, 2025, Metsera received an active acquisition proposal from Novo Nordisk. This event has triggered a potential "scramble" between three major pharmaceutical companies. Metzera's quick response to Novo Nordisk's proposal, just one day after receiving it, shows how attractive this proposal is to the target company's Board of Directors.

1. Superior recommendations from Novo Nordisk and Pfizer's answer

After consultation with external legal and financial counsel, the Metsera Board of Directors has formally determined that Novo Nordisk's proposal constitutes a "Superior Company Proposal" as defined in the Merger Agreement with Pfizer.

The Novo Nordisk proposal values Metsera at up to $77.75 per share, reaching a total transaction value of approximately USD 9.1 billion. This valuation represents an appreciation for Metsera's assets, providing a premium of approximately 133% compared to Metesera's closing price on September 19, 2025, the last trading day before the Pfizer deal was announced. This premium and large total transaction value reflects the superior strategic valuation of Metsera's pharmaceutical assets, particularly obesity treatment products, and confirms the urgency of Novo Nordisk to strengthen its leadership position in the expanding global obesity market[1].

Metsera's public identification of Novo Nordisk's proposal as the Superior Proposal is a strategic move to make full use of the "Fiduciary Out" clause in the original agreement, putting pressure on Pfizer to raise the value of the transaction or adjust terms in Metsera's favor.

The submission of this notice to Pfizer triggered a four-business day negotiation period during which Pfizer has the right to negotiate with Metsera to adjust the terms of the Pfizer Merger Agreement, with the aim of making the Novo Nordisk Proposal no longer constitute an Outstanding Offer in M&A.

However, Pfizer has informed Metsera that it does not believe Metsera has the right to issue this Notice, but Metsera does not agree with Pfizer's position. This legal dispute immediately brings potential legal risks into the antagonistic phase. Although the Metsera Board of Directors has identified the Novo Nordisk Proposal as a Superior Proposal, the Pfizer Merger Agreement remains in effect. As a result, the Metsera Board of Directors is still reaffirming its initial recommendation to shareholders to approve the Pfizer Merger Agreement, until the adversarial period ends and the Board makes a final conclusion.

2. Transaction structure from Novo Nordisk's Superior Proposal

Novo Nordisk's two-step transaction structure is a sophisticated M&A mechanism, designed to ensure immediate financial certainty and economic benefits for Novo Nordisk, while providing high liquidity to Metsera shareholders.

Special capitalization and dividend mechanism

The first step of the Novo Nordisk Transaction will take place immediately following the conclusion of the Novo Transaction Agreements. This mechanism involves two cash transactions of equivalent value:

Cash transactions for Metsera: A subsidiary of Novo Nordisk will pay Metsera a cash amount of $56.50 per Metsera common share, along with certain amounts related to Metsera employee equity and transaction costs.

Special shareholder dividend: On the same day, Metsera will declare a special cash dividend of $56.50 per Metsera common share. The closing date will be ten days after the signing of the Novo Merger Agreement, and the payment will take place shortly thereafter.

This parallel injection and divestment mechanism provides instant and certainty liquidity worth $56.50 per share to shareholders, minimizing the risk of the transaction being canceled for the majority of the value received, making this proposition significantly more attractive than a transaction that depends on extended conditions.

In return for the cash equivalent of $56.50 per share that Novo Nordisk injected, Metsera will issue to Novo Nordisk's subsidiary (Investor Sub) Non-Voting Convertible Preferred Stock.

This structure allows Novo Nordisk to lock in an immediate economic interest in Metsera.

It can be seen that this type of stock represents a total of 50% of Metsera's fully-diluted share capital on a post-issuance basis.

The stock will not have voting rights except in cases where it is required by law or involves a change in its own preference rights. The use of non-voting shares allows Novo Nordisk to achieve a 50% economic benefit without immediately activating control, avoiding issues associated with an early change of control prior to receiving antitrust approval and shareholder approval for Step 2.

The conversion price is set at $56.50 per Metsera common share. These shares are optionally convertible into common shares, and the transfer to a third party (other than Novo's affiliate) will automatically trigger conversion to common shares.

The terms relating to Preferred Shares are designed to protect Novo Nordisk's strategic investment and maintain Metesera's stability in the event of a failed Step 2 merger transaction.

• Initial transfer restrictions:  Until the Novo Merger Agreement is terminated, Preferred Shares are transferable only to an affiliate of Novo Nordisk or in other exceptional circumstances (such as required by law or with the consent of Metsera).
• Post-termination restrictions easing: To prevent an immediate sell-off if the merger agreement collapses, transfer restrictions are only eased over time: after one year of termination of the  Novo Agreement, 50% of the initially issued shares are transferable; and after two years, all remaining shares will be transferable.
• Interim funding: Novo Nordisk will also provide an Interim Funding to meet Metsera's ongoing cash needs, including operating expenses and employee retention bonuses. This loan has no maturity date, accrues interest at 7% per annum (in the form of interest paid in kind - PIK), and is convertible to Non-Voting Convertible Preferred Shares at a price of $56.50. This ensures that sustained capital is converted at the same base valuation.

Risks of the 2nd merger

The second step of the transaction is a formal merger (Merger) after receiving approval from shareholders and regulators. This phase focuses on the valuation of clinical development assets through the Contingent Value Rights (CVR) mechanism.

Once the merger is complete, holders of Metsera common stock and certain employee equity interests will receive one CVR per share.

• Maximum value: CVR represents the right to receive up to USD 21.25 in cash.
• Contractual nature: Each CVR is a non-tradable contractual contingent right. This forces CVR holders to wait for the achievement of specified milestones to receive the corresponding cash payment.
• Consistency in pricing: These CVR milestones are defined as "substantially the same" compared to those proposed in the Pfizer Merger Agreement. This consistency suggests that Metsera's clinical asset valuation is relatively consensus among major bidders in the industry.

A Pfizer researcher at work. Source: GEN

3. Challenges in continuing to implement the Superior Proposal

The Novo Nordisk transaction includes strong legal provisions that protect their strategic investment and create a significant financial barrier to any other bidder.

The Novo Nordisk Merger Agreement will include a standard "no shop" clause, but there is a "fiduciary out" clause that allows Metsera to provide information and enter into negotiations with a third party regarding an unsolicited proposal if the proposal is likely to result in another "Superior Proposal".

In order to accept another Superior Proposal, the Metsera Board of Directors must determine that failure to accept the superior proposal would be inconsistent with its fiduciary duties under applicable law.

In addition, the Superior Proposal's  termination fee structure  is designed to offset the costs incurred when Metsera switches partners from Pfizer to Novo Nordisk and then protects Novo Nordisk from any further competing proposals, which is a significant challenge for the seller to consider this new proposal and abandon the proposal. agreement signed with Pfizer.

Pfizer transition costs: Novo Nordisk commits to pay approximately $190 million in Pfizer Termination Fees to Pfizer in conjunction with the termination of the Pfizer Merger Agreement.

Superior bidding barriers: If Metsera subsequently terminates the Novo Nordisk Agreement to accept a Superior Proposal from another third party (after undergoing the Fiduciary Out process), Metsera will have to pay Novo Nordisk a total of two fees:

1. Novo Termination Fee: USD 227 million.
2. Reimbursement of Pfizer Termination Fee: USD 190 million.

The total fee incurred by Metsera (or other third-party bidder) to break the agreement with Novo Nordisk was USD 417 million. This fee establishes an extremely high financial barrier to any competitor, reflecting Novo Nordisk's confidence and determination to protect the transaction, which aims to make this proposal unsurpassable.

Barrier illustration agreement termination fee

The Novo Nordisk/Metsera transaction structure is a prime example of using sophisticated financial strategies to ensure M&A success in a highly competitive sector.

The two-step structure provides a dual benefit: (1) For Novo Nordisk: Guarantees access and economic benefits (50% of capital) to the strategic asset immediately through non-voting preferred capital. This allows Novo Nordisk to accelerate its R&D integration and prepare for more effective competition in the booming GLP-1/Obesity market. (2) For Metsera Shareholders: Provides the optimal combination of solid liquidity ($56.50/share) and R&D performance-based growth potential (CVR up to $21.25/share). Providing the majority of the value in instant cash minimizes the risk of the transaction being canceled, giving the proposal greater appeal.

This is a deal that shows the complexity and diversity of the parties involved. Even if the parties have already concluded a merger agreement, an attractive and better proposal from a third party can cause significant disturbances and challenges. However, as the seller, this is a great opportunity to make the best choices for shareholders and businesses such as making a better new proposal or at least sitting down to negotiate with the current party to adjust the selling price of the target company at a better price than the original.[2]